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Background: Trastuzumab is a drug used in HER2-positive breast cancer that increases patient survival.
Due to cardiotoxicity is the most important side effect of trastuzumab treatment, cardiac monitoring
should be a priority. The purpose of this study is to evaluate plasma NT-proBNP level and major car-
diovascular risk factors as possible early predictors of trastuzumab-induced cardiotoxicity in HER2-
positive breast cancer patients.
Methods: We conducted a retrospective observational study involving 66 patients with HER2-positive
breast cancer treated with trastuzumab. Left ventricle ejection fraction (LVEF), NT-proBNP values, and
the history of cardiovascular risk factors were collected. Cardiotoxicity was diagnosed considering a
decrease of the LVEF from baseline or clinical manifestation of congestive heart failure. NT-proBNP cut-
off points were considered to establish normal or abnormal values according to patient age.
Results: 27.3% of the patients suffered cardiotoxicity during trastuzumab treatment. Most cases were
diagnosed due to the appearance of cardiac symptomatology (66.7%). Logistic regression analysis showed
a significant association of diabetes mellitus (OR 5.9, 95% CI 1.2e28.5, p ¼ 0.028) and high NT-proBNP
levels (OR 22.0, 95% CI 5.7e85.4, p < 0.0001) with the development of trastuzumab-induced
cardiotoxicity.
Conclusion: NT-proBNP levels above the upper limit of the normal range adjusted to age or diabetes
mellitus seem to be associated with a higher risk of developing cardiotoxicity. However, some limitations
of the present study make necessary further studies aimed to clarify whether NT-proBNP and diabetes-
associated markers determinations can be useful in the monitoring of cardiotoxicity risk in breast cancer
patients undergoing trastuzumab therapy.
© 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
HER2/ErbB2 protein belongs to a group of transmembrane re-
ceptors with intracellular tyrosine kinase activity that is overex-
pressed in 20e25% of human breast cancers and is associated with
aggressive tumor growth and poor prognosis [1]. However, the
appearance in recent decades of targeted therapies against com-
ponents of this family of receptors has provided a revolution in thespital, Avenida de la Inves-
r Ltd. This is an open access articletreatment of this type of tumors. This is partially due to the pos-
sibility of combining targeted therapies with chemotherapy, hor-
mone therapy, and/or other inhibitors. A wide variety of anti-HER2
drugs has been described including trastuzumab, pertuzumab,
lapatinib, neratinib, margetuximab, zenocutuzumab (MCLA-128)
and the antibody-drug conjugate trastuzumab-emtansine (T-DM1),
among others [2,3]. Some of these drugs have provided extensive
clinical experience in treating both early and advanced stages of
breast cancer. Trastuzumab (Herceptin®) is a humanized mono-
clonal antibody that selectively binds to the extracellular domain of
the human epidermal growth factor receptor-2 (EGFR-2, HER2) [4].
1-Year treatment with trastuzumab in the adjuvant setting hasunder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/
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the overall survival of these patients [5].
Despite the benefits of this type of therapy, trastuzumab has
been shown to have a high number of cardiac side effects that can
suppose a significant risk to patients. Similarly to other cytotoxic
drugs such as anthracyclines, numerous cardiac side effects have
been described associated to trastuzumab treatment, including: left
ventricular dysfunction, congestive heart failure (CHF), conduction
and rhythm disturbances, acute coronary syndrome, hypertension,
pericardial pathology, vasospasm and dilated cardiomyopathy [6].
Dilated cardiomyopathy has the poorest prognosis, especially if it
does not respond to conventional heart failure therapy, with a 2-
year mortality of 60% [7]. Different clinical trials using trastuzu-
mab as adjuvant therapy reported an incidence of clinical heart
failure of 1.7%e4.1%, and a left ventricular dysfunction of 7.1%e
18.6% [8]. Even so, the incidence of trastuzumab-induced car-
diotoxicity in clinical practice may be even higher, especially when
combined with other chemotherapy treatments.
To early diagnose trastuzumab-induced cardiotoxicity in pa-
tients with HER2-positive breast cancer, imaging tests are recom-
mended for all patients undergoing treatment with trastuzumab.
Currently, the method of choice is the measurement of the left
ventricular ejection fraction (LVEF) by echocardiography or radio-
nuclide ventriculography (MUGA scan) [9]. Transthoracic echocar-
diography is generally preferred due to its widespread availability,
the absence of ionizing radiation exposure, and its ability to di-
agnose alterations in diastolic function. However, the main disad-
vantage of this technique is that the results present a high degree of
observer-dependent variability, and also vary depending on the
echocardiographic method chosen to calculate LVEF [10]. There are
different protocols issued by various institutions about the clinical
practice recommendations to be carried out in breast cancer pa-
tients being treated with trastuzumab, but all of them follow a
similar scheme: evaluation of baseline heart function before tras-
tuzumab administration, followed by LVEF monitoring every 3
months during the course of treatment [11e14].
Nonetheless, most authors agree that the drop of systolic
function measured by LVEF is often a late phenomenon in the
pathophysiological mechanism of trastuzumab-induced car-
diotoxicity [15]. This means that when we detect a drop in LVEF by
echocardiography there is a high likelihood that severe myocardial
damage has already occurred, so that evaluation of cardiac function
by this method alone substantially reduces the temporal window
for the prevention and treatment of the cardiotoxic effects of
chemotherapy [9,14]. Thus, this finding has led to the search for
more sensitive techniques to detect minimal changes in heart
function in breast cancer patients. In this way, we could achieve an
improvement in the overall prognosis of patients, as well as optimal
control of oncological treatment.
The main objective of this study is to analyze the correlation
between the appearance of cardiotoxicity and the elevation of NT-
proBNP plasma levels in comparison with LVEF measured by
echocardiography, to identify this biomarker as an early predictor
of trastuzumab-induced cardiotoxicity. Besides, we will try to
demonstrate whether patients with certain cardiovascular risk
factors such as smoking, diabetes, hypercholesterolemia, hyper-
tension and increased body mass index, have a higher risk of
developing cardiotoxicity during trastuzumab treatment.
2. Patients and methods
2.1. Study population
We performed a retrospective observational study that
recruited women with breast cancer that were treated with107trastuzumab from the San Cecilio University Hospital in Granada
(Spain). The protocol was approved by the Provincial Ethics Com-
mittee of Granada following the principles set out in the Declara-
tion of Helsinki. The information necessary for the elaboration of
this study was extracted from the computerized medical records of
each patient through the healthcare information system.
To be included in our study, all the patients had to present
HER2-positivity according to the following two criteria: 3þ staining
on immunohistochemistry (IHC), or a positive result on fluores-
cence in situ hybridization (FISH) analysis for HER2 in case of 2þ
staining or less on IHC. The clinical stage of each patient was not an
exclusion criterion and thus early or advanced breast cancer cases
were admitted. Early disease was considered when the tumor was
limited to the breast without invasion to other tissues/organs or
lymph nodes, while advanced disease was diagnosed when any of
these complications were present.
Trastuzumabwas administered as long as the baseline LVEF was
higher than 55%. General guidelines for its administration were the
following: an intravenous infusion of an initial dose of 8 mg/kg,
followed at 21 days by a maintenance dose of 6 mg/kg every three
weeks; or an intravenous infusion of an initial dose of 4 mg/kg,
followed 7 days after by a maintenance dose of 2 mg/kg weekly. If
the drug was well tolerated, either of the two guidelines was
maintained for an average period of 1 year. In those cases in which
the patients had needed neoadjuvant chemotherapy, trastuzumab
was administered together with taxanes (docetaxel or paclitaxel).
The treatment was interrupted in those circumstances in which
trastuzumab-induced cardiotoxicity was suspected, that is, when
clinical manifestations of CHF or other clinical signs suggestive of
cardiotoxicity appeared, as well as in those patients in whom a
decrease in baseline LVEF 10% was detected by echocardiography,
obtaining a LVEF value below 50%.2.2. Clinical examination
Some clinical conditions that have been documented in previous
studies as possible influencing factors on cardiotoxicity associated
with breast cancer chemotherapy treatment were considered.
Among them, we decided to gather information about 5 cardio-
vascular risk factors: smoking, hypertension, diabetes mellitus,
hypercholesterolemia and body mass index (BMI). Regarding the
latter, we decided to divide the patients into three groups: normal
weight (BMI 24.99 kg/m2), overweight (BMI ¼ 25e29.9 kg/m2),
and obesity (BMI 30 kg/m2).2.3. Echocardiography
The echocardiographic method chosen to measure LVEF was the
biplane method of disks (modified Simpson’s rule), which is the
current method recommended by the American Society of Echo-
cardiography for the assessment of LVEF [15]. If this method was
not available, the estimations were carried out using the Teichholz
M-mode method. Measurements were made before chemotherapy
and every 3 months after the introduction of trastuzumab. Car-
diotoxicity was defined as an asymptomatic drop in baseline LVEF
10% with a final value < 50%, or any drop in LVEF accompanied by
signs or symptoms of CHF or another cardiac clinic suggestive of
cardiotoxicity [16e18]. Among the clinical manifestations that were
considered for the appearance of trastuzumab-induced cardiotox-
icity are the following: signs or symptoms of CHF, arrhythmias,
pericarditis with or without pericardial effusion, and dilated car-
diomyopathy with left ventricular systolic dysfunction.
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To obtain NT-proBNP plasma levels, sandwich-type ELISA
(Roche Diagnostics®) were applied from blood samples extracted
from the patients. Blood draws were taken about every 3 months
after starting treatment with trastuzumab. The resulting values
were expressed in pg/ml. Depending on the age group, different NT-
proBNP cut-off points were considered to exclude the diagnosis of
acute cardiac dysfunction [19,20], <125 pg/ml (<50 years),
<300 pg/ml (50 and 75 years) or <450 pg/ml (75 years). Below
10 pg/ml, NT-proBNP plasma levels were considered undetectable.
Since one of the objectives was to correlate NT-proBNP levels with
the appearance of cardiotoxicity, the maximum time elapsed be-
tween each LVEF and NT-proBNP value that we admitted was 30
days with either parameter being measured first.
2.5. Statistical analysis
Qualitative variables were expressed in frequencies and per-
centages, while for quantitative variables both the mean and the
standard deviation were calculated. Normality was checked by
Lilliefors-corrected Kolmogorov-Smirnov test, and the correlation
between NT-proBNP and LVEF was analyzed by Spearman’s rho test
considering all the patients or the association of both variables
within two age groups (<50 and  50 years old). We performed a
logistic regression model to evaluate the impact of cardiovascular
risk factors and NT-proBNP levels (normal vs pathological) on
trastuzumab-induced cardiotoxicity. Furthermore, we calculated
ROC curves to predict the NT-proBNP cut-off points fromwhich the
risk of suffering trastuzumab-induced cardiotoxicity increases.
p < 0.05 were considered statistically significant. All analyses were
performed using IBM SPSS Statistics v.24 software.
3. Results
3.1. Patients
Our study sample consisted of 66 women with HER2-positive
breast cancer diagnosed between 1995 and 2015. The baseline
characteristics of patients are shown in Table 1. The mean time of
clinical follow-up since the diagnosis of the primary tumor was 9.5
years. The mean age of the patients was 50.7 (with a range between
25 and 76), and more than half of them (54.5%) were over 50 years
old. At the beginning of the study, 38 (57.6%) patients had localized
disease while 28 (42.4%) had advanced disease. From the latter
group, 27 patients had nodal involvement confirmed by biopsy,
while 5 had distant metastases. 33 (50%) patients suffered one or
more relapses during disease follow-up, and 19 (28.8%) ended up
dying because of breast cancer.
A three-weekly regimen of trastuzumab (8 mg starting dose)
was administered to 55 patients, and the remaining 11 patients
received a weekly regimen (4 mg starting dose). 33 patients were
treated with the drug at an early stage, whereas 33 were treated at
an advanced stage. The advanced stage group included patients
with localized disease that were initially treated with conventional
chemotherapy but were treated with trastuzumab after nodal or
distant metastases development. We found 6 (18.2%) and 12
(36.4%) cases of cardiotoxicity in the early and advanced stage
groups, respectively. From the total number of women who
received the three-weekly drug regimen, 14 (25.5%) had cardiac
toxicity, and 13 of them presented NT-proBNP values in the path-
ological range adjusted to age. Moreover, in the weekly regimen
group, 4 patients (36.4%) presented adverse cardiac events, and 5
NT-proBNP values above the upper limit of the normal range were
registered.108The number of pairs LVEF and NT-proBNP that could be collected
was not the same for each patient in the study. Table 2 shows the
number of LVEF and NT-proBNP pairs and the number and pro-
portion of patients that correspond to each value. A total of 174
pairs of LVEF and NT-proBNP values were obtained. The mean value
(±SD) of LVEF was 60% (±7.9). The minimum registered was 25%,
while themaximumwas 85%. Likewise, themean level (±SD) of NT-
proBNP was 320.6 pg/ml (±1256.8), with a minimum of 13 pg/ml
and a maximum of 13 913 pg/ml. Table 3 shows the values of both
variables considering two age groups (women <50 years vs women
50 years). 18 patients (27.3%) suffered from trastuzumab-induced
cardiotoxicity. Among them, 6 patients (9.1%) had subclinical car-
diotoxicity, and they were diagnosed by a drop in LVEF 10% by
echocardiography with a resulting LVEF <50%, and 12 patients
(18.2%) presented clinically symptomatic cardiotoxicity at some
point. The remaining 48 patients (72.7%) did not develop
trastuzumab-induced cardiotoxicity at any time during the follow-
up.
3.2. Association between NT-proBNP and LVEF
The correlation test between LVEF and NT-proBNP values
showed a significant correlation between both variables (Spear-
man’s coefficient 0.156, p ¼ 0.040). Considering the referred two
age groups, we found that women under 50 years presented aweak
correlation (0.119) but not significant (p ¼ 0.362). However, in
women 50 years old the correlation was significant (0.194,
p ¼ 0.039).
3.3. Association among NT-proBNP, cardiovascular risk factors and
cardiotoxicity
To assess the effect of cardiovascular risk factors (hypertension,
smoking, hypercholesterolemia, diabetes mellitus and BMI) and
pathological NT-proBNP levels on the appearance of trastuzumab-
induced cardiotoxicity, we performed a binary logistic regression
analysis. The model was statistically significant with c2 ¼ 27.059
and p < 0.0001. From the 6 predictor variables of cardiotoxicity,
only diabetes and pathological levels of NT-proBNP, were statisti-
cally significant with a p < 0.05 and a 95% confidence interval (CI)
that excluded the null value of odds ratio (OR). Thus, for diabetes,
we obtained an adjusted OR ¼ 5.861 (95% CI: 1.206e28.496) and a
p ¼ 0.028. For NT-proBNP levels we found an adjusted OR ¼ 22.039
(95% CI: 5.689e85.385) and a p < 0.0001. Table 4 summarizes the
information extracted from the regression analysis of these two
variables.
3.4. ROC curve for the diagnosis of cardiotoxicity
The diagnostic validity of NT-proBNP as a cardiotoxicity
biomarker was evaluated using the non-parametric ROC curve, in
which the Y-axis corresponds to sensitivity and the X-axis repre-
sents the false positive rate (1e specificity). The area under the ROC
curve (AUC) was 0.879 (95% CI: 0.793e0.965), with a standard error
of 0.044. This AUC was statistically significant, with a p < 0.0001.
Besides that, we obtained an optimal cut-off point of NT-proBNP of
206.5 pg/ml, considering as maximum values a sensitivity ¼ 75%
and a specificity ¼ 88% (Youden index ¼ 0.63) (Fig. 1A).
Considering two age groups, only the ROC curve for patients
50 years oldwas statistically significant (p< 0.0001). The AUCwas
0.874 (95% CI: 0.771e0.977), with a standard error of 0.053. The
optimal cut-off point of NT-proBNP found in this group was
239.5 pg/ml, taking into account as maximum achievable values a
sensitivity ¼ 79% and a specificity ¼ 87% (Youden index ¼ 0.65)
(Fig. 1B). On the contrary, in women <50 years of age, we could not
Table 1
Baseline patient characteristics and treatment.a.
Characteristic Cardiotoxicity (n ¼ 18) No cardiotoxicity (n ¼ 48) Total (n ¼ 66)
Age at diagnosis (years)
Mean [±SD] 53.22 [11.23] 49.79 [11.88] 50.73 [11.72]
Range 31e71 25e76 25e76
<50 years old 6 (9.1) 24 (36.4) 30 (45.5)
50 years old 12 (18.2) 24 (36.4) 36 (54.5)
Menopausal status
Premenopause 6 (9.1) 28 (42.4) 34 (51.5)
Postmenopause 12 (18.2) 20 (30.3) 32 (48.5)
Estrogen receptor status
Negative (<1%) 10 (15.2) 17 (25.8) 27 (40.9)
Positive (1%) 8 (12.1) 31 (47.0) 39 (59.1)
Progesterone receptor status
Negative (<1%) 8 (12.1) 18 (27.3) 26 (39.4)
Positive (1%) 10 (15.2) 30 (45.5) 40 (60.6)
Ki-67
Negative (<20%) 4 (6.0) 5 (7.6) 9 (13.6)
Positive (20%) 12 (18.2) 25 (37.9) 37 (56.1)
Unknown 20 (30.3)
HER2 Ile655Val polymorphism
Ile/Ile genotype 4 (6.1) 20 (30.3) 24 (36.4)
Ile/Val genotype 8 (12.1) 9 (13.6) 17 (25.8)
Val/Val genotype 0 1 (1.5) 1 (1.5)
Unknown 24 (36.4)
Histological type
Invasive ductal 17 (25.8) 45 (68.2) 62 (93.9)
Invasive lobular 0 1 (1.5) 1 (1.5)
Others 1 (1.5) 2 (3.0) 3 (4.5)
Tumor grade
G-I 0 0 0
G-II 13 (19.7) 30 (45.5) 43 (65.2)
G-III 4 (6.0) 12 (18.2) 16 (24.2)
Unknown 7 (10.6)
Stage
Stage I 3 (4.5) 16 (24.2) 19 (28.8)
Stage II 11 (16.7) 14 (21.2) 25 (37.9)
Stage III 2 (3.0) 5 (7.6) 7 (10.6)
Stage IV 1 (1.5) 4 (6.1) 5 (7.6)
Unknown 10 (15.2)
BMI (kg/m2)
Normal weight (18.50e24.99) 5 (7.6) 17 (25.8) 22 (33.3)
Overweight (25.00e29.99) 4 (6.1) 21 (31.8) 25 (37.9)
Obesity (30.00) 9 (13.6) 10 (15.2) 19 (28.8)
HBP
Yes 8 (12.1) 13 (19.7) 21 (31.8)
No 10 (15.2) 35 (53.0) 45 (68.2)
DM
Yes 4 (6.1) 4 (6.1) 8 (12.1)
No 14 (21.2) 44 (66.7) 58 (87.9)
Hypercholesterolemia
Yes 10 (15.2) 19 (28.8) 29 (43.9)
No 8 (12.1) 29 (43.9) 37 (56.1)
Tobacco use
Non-smoker 11 (16.7) 26 (39.4) 37 (56.1)
Smoker 4 (6.1) 14 (21.2) 18 (27.3)
Former smoker 3 (4.5) 8 (12.1) 11 (16.7)
Treatment
Neoadjuvant 4 (6.1) 14 (21.2) 18 (27.3)
Adjuvant 11 (16.7) 23 (34.8) 34 (51.5)
Both 2 (3.0) 8 (12.1) 10 (15.2)
None 1 (1.5) 3 (4.5) 4 (6.1)
Radiotherapy
Yes 17 (25.8) 43 (65.2) 60 (90.9)
No 1 (1.5) 5 (7.6) 6 (9.1)
Chemotherapy
Anthracyclines 3 (4.5) 15 (22.7) 18 (27.3)
Taxanes 0 3 (4.5) 3 (4.5)
Both 14 (21.2) 26 (39.4) 40 (60.6)
Other drugs 0 1 (1.5) 1 (1.5)
None 1 (1.5) 3 (4.5) 4 (6.1)
Trastuzumab emtansine
Yes 1 (1.5) 3 (4.5) 4 (6.1)
No 17 (25.8) 45 (68.2) 62 (93.9)
BMI: body mass index; HBP: high blood pressure; DM: diabetes mellitus; SD: standard deviation.
a Values are n (%) or mean [SD].
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Table 2
LVEF and NT-proBNP value pairs obtained from breast cancer patients
treated with trastuzumab.











Distribution of LVEF and NT-proBNP according to age.
<50 years 50 years
LVEF Frequency 61 113
Mean 60.6% 59.7%
SD 6.3 8.7
NT-proBNP Frequency 61 113
Mean 99 pg/ml 440.2 pg/ml
SD 77.4 1547.7
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4. Discussion
Cardiac side effects associated with trastuzumab treatment may
seriously compromise the prognosis and well-being of patients
with HER2-positive breast cancer. The incidence of trastuzumab-Table 4
Logistic regression analysis of the risk of cardiotoxicity during trastuzumab treatment in br
proBNP values adjusted to age were statistically significant.
b S.E. Wald statistic
Diabetes 1.768 0.807 4.803
NT-proBNP ˃ ULN 3.093 0.691 20.033
ULN: Upper limit of the normal range of NT-proBNP values adjusted to age.
Fig. 1. ROC curves of plasma NT-proBNP levels for the diagnosis of cardiotoxicity during tras
the study (A) or those patients aged 50e75 years old (B).
110induced cardiotoxicity varies by series but is estimated to range
from 1.7% when used alone to approximately 20% when used in
combination with other chemotherapy drugs such as anthracy-
clines or cyclophosphamide. In clinical practice, however, these
percentages rise even higher, as seen in numerous clinical trials in
which the number of cardiac side effects after adjuvant treatment
with trastuzumab was prospectively evaluated, such as the rate of
left ventricular dysfunction ranged from 7 to 34%, with heart failure
rates between 0 and 4% [21].
There are currently two types of cardiotoxicity secondary to the
chemotherapy administration. Type I, characteristic of anthracy-
clines, appears to be due to the direct oxidative stress-induced
death of cardiomyocytes. It is an irreversible, dose-dependent and
easily identifiable process at myocardial biopsy [22]. Conversely,
type II corresponds to trastuzumab-induced cardiotoxicity, char-
acterized by a transient deterioration of myocardial function
without resulting in cell death. It is not a dose-dependent process
and, in most cases, reversible so that the drug can be readminis-
tered once the myocardial function has been recovered [9].
The etiopathogenesis of trastuzumab-induced cardiotoxicity is
not fully clarified. Some authors advocate a “multiple hit” hy-
pothesis, in which the chemotherapy drug would cause direct
damage to the cardiomyocyte, while the involvement of other risk
factors would have an indirect and synergistic effect, increasing the
risk of cardiotoxicity [23]. Following this theory, several risk factors
have been identified that are related to an increased risk of
trastuzumab-induced cardiotoxicity. One of the most important is
the concurrent administration of anthracyclines. It has beenwidely
demonstrated that there is a clear relationship between the cu-
mulative dose of anthracyclines and trastuzumab-induced car-
diotoxicity. A meta-analysis of 11882 patients showed an increasedeast cancer patients. From all the factors considered, only diabetes and abnormal NT-
p-value Exp (b) 95% CI for Exp (b)
Lower Upper
0.028 5.861 1.206 28.496
<0.0001 22.039 5.689 85.385
tuzumab treatment in breast cancer patients. ROC curves considering all the patients in
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anthracyclines together compared to those who only received
trastuzumab [24]. In the study carried out by Breast Cancer Inter-
national Research Group, the clinical heart failure rate was 5 times
lower in the group of patients treated with trastuzumab without
anthracyclines [25]. This association between anthracyclines and
trastuzumab leads to the conclusion that when both therapies are
administered concomitantly or separated by a maximum time in-
terval of 90 days, the incidence of left ventricular dysfunction and
congestive heart failure rises to 28% and 27% respectively [26]. In
fact, the risk decreases as the time between the administration of
both drugs increases, with an incidence of 4.3% if the period time is
longer than 90 days [27]. Other factors influencing trastuzumab-
induced cardiotoxicity are advanced age, previous radiation ther-
apy and cardiovascular risk factors. In a retrospective analysis,
women ˃ 65 years of age had an increased risk of cardiotoxicity
when treated with trastuzumab, with a hazard ratio (HR) ¼ 2.08
[28]. The risk of cardiotoxicity is higher in patients treated with
cardiotoxic chemotherapy (including trastuzumab) and left breast
radiotherapy, suggesting a synergistic effect of the latter one on
cardiac risk [29]. Cardiovascular risk factors such as hypertension,
smoking, obesity, diabetes mellitus, coronary artery disease, atrial
fibrillation or renal failure, which lead to an increased risk of
developing heart failure 3 years after initiating treatment with
trastuzumab, especially in older women, with a maximum inci-
dence of 45% [30].
Given the magnitude of the problem coupled with the limita-
tions of echocardiography, multiple studies have been conducted to
identify other biomarkers as possible early predictors of
trastuzumab-induced cardiotoxicity. Plasmatic biomarkers could
complement echocardiographic screening techniques due to their
easy obtaining (a simple blood draw) and interpretation, cost-
effectiveness, and most of all, their relationship with myocardial
injury in patients with heart failure [31]. Two biomarkers have been
widely studied as predictive factors for the early diagnosis of
trastuzumab-induced cardiotoxicity: cardiac troponins and natri-
uretic peptides.
Troponin I elevation has been shown in several studies to be
associated with a 17.6-fold increase in the risk of trastuzumab-
induced cardiotoxicity, as well as a lower probability of LVEF re-
covery after treatment interruption [32]. This has led several or-
ganizations to consider the use of troponin I as an early marker of
cardiotoxicity secondary to the treatment with trastuzumab, as is
the case with the consensus established by the American Society of
Echocardiography and the European Association of Cardiovascular
Imaging [12].
Studies on natriuretic peptides are contradictory. Brain natri-
uretic peptide (BNP) and its precursor, N-terminal pro-brain
natriuretic peptide (NT-proBNP), are both secreted in response to
ventricular wall distension and associated with the appearance of
CHF in patients with left ventricular overload [33]. Some studies
indicate that variations in NT-proBNP concentrations may correlate
with the risk of cardiotoxicity caused by anthracyclines. De Iuliis
et al. developed a prospective study that recruited HER2-positive
breast cancer patients treated with trastuzumab in combination
with anthracyclines and taxanes. Echocardiographic measure-
ments, as well as NT-proBNP determinations, were performed
before starting treatment (T0), at 3 months (T1), at 6 months (T2),
and one year after starting treatment (T3). A significant increase in
NT-proBNP concentrations was observed in T1, T2 and T3
(p < 0.0001) with values 4 times higher than those measured in T0,
even in absence of clear changes in LVEF measured by echocardi-
ography. In addition, NT-proBNP was the only prognostic
biomarker related to mortality after 1 year from the start of
chemotherapy, being the most significant values those measured at1116months (T2) and one year after (T3): NT-proBNP T2 (AUC¼ 0.788;
95% CI: 0.631e0.901; p ¼ 0.0003) and NT-proBNP T3 (AUC ¼ 0.859;
95% CI: 0.712e0.948; p < 0.0001) [34]. Another example is the
research conducted by Urun et al., which managed to establish a
correlation between NT-proBNP levels above 300 pg/ml and an
increased risk of symptomatic heart failure and a lower probability
of later recovery in patients treated with trastuzumab [35]. Addi-
tionally, Zardavas et al. observed an increase in baseline NT-proBNP
levels in patients with cardiotoxicity associated with trastuzumab
administration compared to those who did not. Besides, a Cox
regression model was designed to assess the influence of increases
in NT-proBNP values on time to significant LVEF drop. The results of
the multivariate analysis were as follows: HR ¼ 1.03 (95% CI:
1.02e1.03) with a value of p < 0.001. This resulted in an increase in
the risk of cardiotoxicity ˃ 30% for each 10 ng/dl increase in NT-
proBNP concentration [36].
All these studies along with other authors’ conclusions [37,38]
contribute to support the results found in the present study. We
have found that there is an inverse relationship between LVEF and
NT-proBNP levels in patients with HER2-positive breast cancer.
Also, we have found that those patients with NT-proBNP levels
above the upper limit of normal range adjusted to age or who
present diabetes mellitus as associated comorbidity have a higher
risk of developing cardiotoxicity after administration of trastuzu-
mab than those without any of these conditions (OR ¼ 22.039 and
OR ¼ 5.861, respectively). These findings, if confirmed in prospec-
tive studies, could lead to an important change in the prognosis of
patients treated with trastuzumab, as those factors would allow
detecting those patients with an increased risk of cardiotoxicity. In
this way, we could interrupt the treatment before potentially lethal
structural changes in the myocardium may occur.
Still, there are many other studies whose results are opposed to
them, rejecting NT-proBNP as a diagnostic biomarker of
trastuzumab-induced cardiotoxicity [39e43]. To dissolve these
discrepancies, we require additional studies about the role of NT-
proBNP in the early diagnosis of trastuzumab-related acute car-
diac dysfunction in breast cancer patients, although our data sug-
gest that NT-proBNP levels above the upper limit of the normal
range adjusted to age may correlate with the occurrence of
cardiotoxicity.
Concerning the role of diabetes mellitus in trastuzumab-
induced cardiotoxicity, there appears to be a clear relationship
between this comorbidity and an increased risk of adverse cardiac
events, as our results are endorsed by extensive scientific evidence.
The study conducted by Serrano et al. on women 70 years of age
showed that those patients who were on treatment with trastu-
zumab and had diabetes presented a higher risk of developing
cardiotoxicity with or without symptoms (p ¼ 0.010) [44]. Another
cohort study conducted by Ezaz et al. with 1664 patients aged from
67 to 94 years showed that both previous history of coronary artery
disease (HR ¼ 2.16; 95% CI: 1.21e3.86; p ¼ 0.009) and diabetes
(HR ¼ 1.50; 95% CI: 1.03e2.18; p ¼ 0.034) were associated with a
higher rate of heart failure and cardiomyopathy 3 years after
treatment with trastuzumab [30]. Urun et al. also correlated dia-
betes and a high BMI with an increased risk of cardiotoxicity
(p ¼ 0.002 and p ¼ 0.004, respectively) [35]. Finally, we highlight a
meta-analysis of 6527 patients who were treated with trastuzu-
mab, which showed an association between adverse cardiac effects
derived from its use with risk factors such as hypertension
(OR ¼ 1.61; 95% CI: 1.14e2.26; p < 0.01), diabetes (OR ¼ 1.62; 95%
CI: 1.10e2.38; p < 0.02), previous use of anthracyclines (OR ¼ 2.14;
95% CI: 1.17e3.92; p < 0.02) and advanced age (p ¼ 0.013) [45]. All
this supports the hypothesis that diabetes is an important risk
factor for trastuzumab-induced cardiotoxicity, so special care
should be taken into account in these patients. In that regard, it
I. Blancas, F.J. Martín-Perez, J.M. Garrido et al. The Breast 54 (2020) 106e113would be useful to perform cardiac function controls before
chemotherapy administration, to schedule serial echocardiography
in a shorter time frame than in the rest of the population, and of
course, to achieve a strict glycemic control to avoid disease pro-
gression and thus, the deterioration of myocardial function.
Regarding other cardiovascular risk factors, although our study has
not been able to establish statistically significant associations with
trastuzumab-induced cardiotoxicity, other studies have demon-
strated a correlation betweenmajor cardiovascular risk factors such
as hypertension, obesity or smoking with an increased risk of car-
diotoxicity [46e48].
Apart from the above, our study has some limitations. We must
advise the current lack in the scientific literature of a universal
consensus on the definition of trastuzumab-induced cardiotoxicity.
The criteria used by the oncologists in our study to discontinue
treatment with trastuzumab were based on the definition of car-
diotoxicity used in the Herceptin Adjuvant (HERA) trial carried out
by Suter et al., according to which cardiotoxicity is considered any
decrease in LVEF accompanied by symptoms of CHF, or a decrease in
baseline LVEF  10% with a resultant value < 50% in asymptomatic
patients [18]. However, not all studies conducted to date follow this
definition. For example, the occurrence of cardiotoxicity according
to the Cardiac Review and Evaluation Committee supervising
trastuzumab clinical trials is given by one or more of the following
facts: (1) reduction of LVEF, either global or more specific and se-
vere in the interventricular septum; (2) symptoms or signs asso-
ciated with CHF; (3) associated signs of CHF, including but not
limited to S3 gallop, tachycardia, or both; and (4) decline in LVEF of
at least 5% to < 55% in the presence of signs or symptoms of CHF, or
a reduction in LVEF  10% to < 55% without signs or symptoms of
CHF [49]. Another definition is the one established by the
consensus of the American Society of Echocardiography together
with the European Association of Cardiovascular Imaging, based on
a decrease in LVEF ˃ 10% with a resulting value < 53%, and being
confirmed 2e3 weeks after initial diagnosis by a new imaging
technique [12]. This lack of agreement makes it difficult to compare
the results of our study with those of others who were guided by a
different definition of cardiotoxicity.
Moreover, the study population analyzed included only 66 pa-
tients. This limitation is even more relevant in certain subgroups,
such as the number of patients treated with anthracyclines or
taxanes (18 and 3, respectively), or those affected by diabetes (8), a
factor that showed statistically significant association with car-
diotoxicity. The small sample size may bias the results of our study
due to a possible heterogeneous distribution of prognostic vari-
ables. Furthermore, the patient inclusion period lasted from 1995 to
2015, and since then, there may be differences in diagnostic
methods, especially concerning the sensitivity of echocardiography
and NT-proBNP plasma level determination.
Another limitation is the fact that in 43.9% of patients it was only
possible to obtain a single pair of LVEF and NT-proBNP values,
which precludes the analysis of the intra-individual variability in
these patients. Moreover, baseline NT-proBNP values before drug
administration were not available, and the change of LVEF values
may have been preceded by NT-proBNP increments within a
maximum interval of 30 days or vice versa.
Finally, we must also emphasize the role of additional adjuvant
treatments as possible effect modifiers. In our study sample, more
than 90% of patients were treated with chemotherapy drugs before
or in combination with trastuzumab (27.3% anthracyclines, 4.5%
taxanes, and 60.6% both). Moreover, 90.9% received adjuvant
radiotherapy after surgery. As we mentioned before, both treat-
ments have a synergistic effect on trastuzumab-induced
cardiotoxicity.
The limitations exposed above make it difficult to ensure the112role of NT-proBNP as an early marker of cardiotoxicity during
trastuzumab treatment in breast cancer, raising the possibility that
NT-proBNP elevation may be a consequence of cardiotoxicity or
trastuzumab administration rather than being a predictive factor of
cardiotoxicity.
5. Conclusion
Evaluating the association of trastuzumab-induced cardiotox-
icity during breast cancer treatment with different factors, we have
found that there is an inverse relationship between LVEF and NT-
proBNP plasma levels. Also, we have found that NT-proBNP levels
above the upper limit of the normal range adjusted to age or dia-
betes mellitus may be associated with a higher risk of developing
cardiotoxicity during trastuzumab treatment. However, some lim-
itations of the present study regarding sample size and amount of
data, among others, make necessary further studies aimed to clarify
whether NT-proBNP and diabetes-associated markers de-
terminations can be useful in the monitoring of cardiotoxicity risk
in breast cancer patients undergoing trastuzumab therapy.
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